Deutsche Bank is out with its report today on Nektar Therapeutics NKTR, lowering its PT from $14 to $11.
In its report, Deutsche Bank writes, "Reflecting recent multiple compression in the sector, we are reducing our 12 month price target to $11 (from $14), based on 20x (vs 25x previously) our 2015 EPS est, discounted at 25% for three years."
Deutsche Bank maintains Buy on NKTR.
Shares of NKTR closed Friday at $5.35, down 0.74% from Thursday's close.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Posted In: Analyst ColorPrice TargetAnalyst RatingsDeutsche BankHealth CareLife Sciences Tools & Services
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in